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Abstract	
Hypothesis.	Gene4c	altera4ons	suitable	for	targeted	therapy	are	poorly	known	issues	in	
pulmonary	sarcomatoid	carcinoma	(PSC),	an	uncommon	and	life-threatening	family	of	non-
small	cell	lung	cancer.	
Methods.	Ninety-eight	PSC	were	assessed	for	MET	and	ALK	status	by	fluorescence	in	situ	
hybridiza4on	(FISH)	and	relevant	protein	expression	by	immunohistochemistry	(IHC)	also	
taking	advantage	of	phosphorylated	(p-)	an4bodies.	Moreover,	ALK	and	MET	mRNA	levels	by	
real-4me	PCR	and	western	blot	analysis	for	downstream	ac4va4on	pathways	involving	p-MET,	
p-AKT,	p-MAPK,	p-SRC	and	p-FAK	were	also	determined.	
Results.	MET	amplifica4on	upon	FISH	was	found	in	25/98	(25.6%)	and	ALK	amplifica4on	(but	
not	the	relevant	rearrangement)	in	16/98	(16.3%)	PSC,	with	all	ALK-amplified	tumors	also	
showing	MET	amplifica4on	(p<0.0001).	Nine	PSC,	however,	showed	MET	amplifica4on	
without	any	ALK	gene	altera4on.	ALK	protein	expression	was	always	lacking,	while	MET	and	
p-MET	were	confined	to	the	relevant	amplified	tumors	only.	Increased	ALK	and	MET	mRNA	
levels	were	detectable	in	tumors,	with	no	direct	rela4onship	between	mRNA	content,	protein	
expression	or	FISH	altera4ons.	Western	blot	assays	showed	complete	ac4va4on	of	
downstream	signal	pathways	up	to	p-SRC	and	p-FAK	recruitment	in	MET&ALK	co-amplified	
tumors	only,	whereas	isolated	MET	amplifica4on,	MET&ALK	borderline	amplifica4on	(5-10%	
tumor	cells	with	≥15	copies	of	the	relevant	gene)	or	nega4ve	tumors	showing	eusomy	or	
chromosome	polysomy	were	confined	to	p-MAPK,	p-AKT	and/or	p-MET	ac4va4on.	
Mul4variate	survival	analysis	pushed	a	higher	percentage	of	MET	altered	cells	or	a	higher	
value	of	MET	copy	gain	per	cell	to	marginally	emerge	for	OS	(p=0.140)	and	DFS	(p=0.060),	
respec4vely.	
Conclusions.	ALK	and	MET	seemed	to	act	as	synergic,	non-random	co-ac4vators	of	
downstream	signal	when	co-amplified	in	a	subset	of	PSC	pa4ents,	thus	likely	sugges4ng	a	
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combined	mechanism	of	oncogene	addic4on.	These	altera4ons	could	be	a	suitable	target	for	
therapy	upon	specific	inhibitors.	
Introduc4on	
Pulmonary	sarcomatoid	carcinoma	(PSC)	makes	up	a	rare	(2-3%)	but	deadly	family	of	non-
small	cell	lung	carcinoma	(NSCLC)	encompassing	pleomorphic	carcinoma	(PLC)	(the	most	
frequent),	spindle	cell	carcinoma	(SpCC),	giant	cell	carcinoma	(GCC),	carcinosarcoma	(CS)	and	
pulmonary	blastoma	(PB)	1.	They	are	deemed	to	be	monoclonal	tumor	growths,	in	which	
stable	and	huge	epithelial-mesenchymal	transi4on	(EMT)	takes	place	causing	sarcoma-like	
and/or	sarcoma	elements	to	arise	1-8.	As	sensi4vity	of	PSC	to	current	medical	manipula4ons	
with	pla4num-based	doublets,	sarcoma-specific	regimens	or	radiotherapy	is	disappoin4ng,	
rever4ng	EMT	or	targe4ng	specific	oncogene	addic4on	mechanisms	could	be	suitable	therapy	
op4ons	for	such	a	life-threatening	tumor	family	9-12.	However,	the	lack	of	specific	PSC-
oriented	clinical	trials,	the	inherent	rarity	of	these	tumors	along	with	troubles	in	their	
diagnos4c	recogni4on	and	the	scarce	understanding	of	the	biological	mechanisms	underlying	
the	development	and	progression	of	these	tumors	explain	the	current	unsuitability	for	a	
more	effec4ve	clinical	management	beyond	surgical	excision	1,	2,	11,	12.	Therefore,	
addi4onal	gene4c	tes4ng	with	a	variety	of	experimental	tools	could	allow	new	targets	of	
personalized	interven4on	to	be	established	along	with	the	relevant	selec4on	criteria	for	
pa4ents	to	iden4fy.	Taking	into	account	the	enormous	prevalence	and	the	social	relevance	of	
lung	cancer	in	the	human	popula4on	worldwide	13,	even	rare	tumors	such	as	PSC	are	
clinically	meaningful	at	the	level	of	individual	pa4ents.	
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A	non-random	amplifica4on	but	not	structural	rearrangement	of	anaplas4c	lymphoma	kinase	
(ALK)	gene	has	recently	been	documented	in	about	18%	PSC	by	means	of	fluorescence	in	situ	
hybridiza4on	(FISH)	analysis	14.	As	no	ALK	protein	accumula4on	was	consistently	observed	
upon	sensi4ve	immunohistochemistry	(IHC)	methods,	another	synergic	gene	driver	
mechanism	was	hypothesized	to	be	in	charge	of	the	development	and	maintenance	of	these	
tumors,	such	as	MET	gene,	which	is	recurrently	altered	in	a	subset	of	PSC	14,	15,	with	
significant	func4onal	differences	with	lung	adenocarcinoma	16-19.	More	recently,	it	has	been	
published	that	muta4onal	events	of	MET	leading	to	exon	14	skipping	are	poten4ally	
targetable	events	in	PSC	11	but	the	relevance	of	this	muta4on	has	been	diversely	reported	on	
12.	Most	importantly,	the	role	of	MET	amplifica4on	and	its	func4onal	interplay	with	ALK	
altera4ons	s4ll	remains	an	unresolved	issue.		
Beyond	func4oning	as	a	driver	gene	in	the	development	of	PSC	and	an	adverse	prognos4c	
factor	in	lung	cancer	20,	MET	is	also	recruited	as	a	primary	or	secondary	resistance	
mechanism	to	tyrosine	kinase	inhibitor	(TKI)	treatment	in	EGFR-mutated	lung	
adenocarcinoma	21-24,	whereas	de	novo	MET	amplifica4on	is	restricted	to	about	3-5%	of	
chemo-naïve	adenocarcinoma	pa4ents	16,	23,	25.	
This	study	was	aimed	at	evalua4ng	the	status	of	MET	and	the	rela4ve	interplay	with	ALK	in	a	
consecu4ve	series	of	PSC,	the	largest	one	to	be	assessed	thus	far	for	either	biomarker,	by	
using	several	experimental	approaches,	such	as	FISH,	IHC,	real-4me	polymerase	chain	
reac4on	(qPCR)	and	func4onal	ac4va4on	upon	western	blot	(WB).	The	main	goal	was	to	offer	
a	biological	ra4onale	to	the	func4onal	u4liza4on	of	MET	as	suitable	target	of	therapy	in	these	
life-threatening	tumors.	
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Pa4ents	and	Methods	
Overall	design	of	the	study	
Cases	were	screened	for	ALK	and	MET	gene	status	abnormali4es	by	means	of	FISH	and	for	
the	relevant	expression	by	using	enzyma4c	IHC,	either	total	or	phosphorylated	(p)	protein.	
Subsequently,	the	func4onal	meaning	of	the	diverse	gene	altera4ons	was	further	untangled	
by	addressing	real-4me	PCR	to	evaluate	the	mRNA	levels	and	western	blot	analysis	to	
decipher	the	relevant	downstream	func4onal	ac4va4on	signals	upon	MET/p-MET,	ALK/p-ALK,	
AKT/p-AKT,	MAPK/p-MAPK,	SRC/p-SRC	and	FAK/p-FAK	simultaneous	assessment.	
Pa4ents	and	tumors	
A	series	of	98	consecu4ve	surgical	specimens	of	PSC	from	76	males	(range	38-85	years;	mean
±SD	67.2±10.3)	and	22	females	(range	30-83	years;	mean±SD	61.2±14.1)	were	retrieved	from	
the	pathology	archives	of	the	par4cipant	Ins4tu4ons.	The	lack	of	a	previous	history	of	cancer	
elsewhere	in	the	body	and	the	availability	of	complete	clinical	informa4on	were	required	for	
entering	the	study.	Eighty-one	pa4ents	were	current	smokers,	seven	former	smokers	and	six	
never	smokers	(smoking	status	was	unavailable	in	four	pa4ents).	
Surgical	specimens	consisted	of	77	(bi)-lobectomies,	18	pneumonectomies	and	three	
segmentectomies.	According	to	the	7th	edi4on	of	the	TNM	staging	system,	there	were	seven	
tumors	staged	IA,	14	IB,	23	IIA,	28	IIB,	24	IIIA,	one	IIIB	(featuring	pT4pN2)	and	one	IV	
(featuring	pT3pN1pM1a).	In	detail,	there	were	six	pT1a,	eight	pT1b,	25	pT2a,	18	pT2b,	36	pT3	
and	5	pT4	along	with	57	pN0,	25	pN1	and	16	pN2	pa4ents	and	a	percentage	of	involved	
lymph	nodes	ranging	from	4	to	83%.	Vascular	invasion	was	observed	in	62	tumors	and	
necrosis	in	93	tumors	(the	lacer	ranging	from	5%	to	85%	of	the	en4re	tumor	mass).	Pleural	
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invasion	26	was	documented	in	63	tumors	resul4ng	in	30	PL1,	11	PL2	and	22	PL3.	Tumor	size	
ranged	from	3	to	150	mm,	with	a	mean±SD	value	of	41.1±28.4	mm.	Among	pa4ents,	14	
underwent	neo-adjuvant	chemotherapy	(for	other	15	pa4ents	this	informa4on	was	
unavailable).	Follow-up	informa4on	was	updated	to	July	2015.	During	this	period,	48	pa4ents	
had	recurrent	disease	(17	single,	18	mul4ple	and	13	systemic	relapses)	and	58	died	of	
disease,	with	the	mean	disease-free	and	overall	survival	4me	being	28.9±37.9	months	
(median	9	mo;	range	1-165	mo)	and	33.6±35.4	months	(median	20.3	mo;	range	1-165	mo),	
respec4vely.	Overall	data	concerning	the	98	PSC	pa4ents	under	evalua4on	are	summed	up	in	
Table	1.			
All	PSC	samples	had	been	fixed	in	4%	buffered	formaldehyde	solu4on	for	12-24	hours	and	
embedded	in	paraffin	according	to	standard	histopathology	methods.	All	the	original	
hematoxylin	and	eosin	stained	sec4ons	were	reviewed	on	the	basis	of	the	2015	WHO	lung	
cancer	classifica4on	1,	without	knowledge	of	pa4ents’	iden4ty	or	original	tumor	
categoriza4on.	Moreover,	frozen	samples	of	PSC	and	lung	adenocarcinoma	(the	lacer	serving	
as	control	group	for	either	MET	and	ALK	altera4ons)	were	available	for	the	study.	
Ethics	
The	study	was	no4fied	to	and	approved	by	the	independent	ethics	commicee	of	the	
“Fondazione	IRCCS	Is4tuto	Nazionale	Tumori”,	Milan,	Italy	(accession	number	INT-162/14).	All	
pa4ents	gave	their	wricen	consent	for	diagnosis	and	research	ac4vi4es	upon	hospital	
admicance.		
Fluorescence	in	situ	hybridiza4on	
  	8
Pelosi	et	al,	MET	and	ALK	altera4ons	in	pulmonary	sarcomatoid	carcinoma,	JTO-D-15-01313-R1
Fluorescence	in	situ	hybridiza4on	analysis	was	performed	in	2-4	μ-thick	paraffin	sec4ons	by	
coun4ng	at	least	100	tumor	cells.	Briefly,	a	commercial	available	break-apart,	dual-color	gene	
specific	probe	at	2p23	(Abboc	Molecular,	Vysis®	LSI®	ALK	Dual	Color,	Break	Apart	
Rearrangement	Probe)	was	used	to	iden4fy	ALK	altera4ons,	whereas	MET	was	inves4gated	by	
means	of	a	commercial	available	dual-color	probe	at	7q31	along	with	CEP	probe	for	
chromosome	7	centromere	(ZytoLight®	SPEC	MET/CEN	7	Dual	Color	Probe,	Bio-Otpica,	Milan,	
Italy).	Both	probes	were	used	according	to	the	manufacturer’s	instruc4ons,	analyzing	
separately	both	the	epithelial	and	sarcoma/sarcoma-like	components	on	the	same	areas	of	
tumor	sec4ons.	For	ALK,	two	or	more	red/green	fusion	signals	(yellowish)	indicated	cells	with	
wild-type	configura4on,	whereas	one	or	more	yellowish	fusion	signals	(wild	type	ALK)	along	
with	separate	green	and	red	signals,	or	isolated	red	signals,	iden4fied	cells	with	rearranged	
gene.	For	ALK	and	MET	amplifica4on,	quite	restric4ve	criteria	were	taken	into	account	as	
follows:	(a)	amplifica4on,	if	more	than	10%	tumor	cells	presented	with	≥15	copies	of	the	
relevant	genes	or	variably	sized	signal	clusters;	(b)	borderline	amplifica4on,	if	5-10%	tumor	
cells	presented	with	≥15	copies	of	the	relevant	gene	or	variably	sized	signal	clusters;	(c)	
eusomy,	if	tumor	cells	showed	2	to	4	signals	regardless	of	their	percentage	or	<5%	tumor	cells	
presented	with	amplifica4on	criteria	(≥15	copies	of	the	relevant	gene	or	variably	sized	signal	
clusters)	14,	16.	We	preferred	to	use	this	way	to	express	MET	and	ALK	altera4ons	rather	than	
the	ra4o	between	gene	and	centromere	signals	for	at	least	two	reasons:	a)	different	
experimental	condi4ons	in	the	FISH	analysis	for	MET	and	ALK,	with	dual-color	assay	for	the	
former	allowing	simultaneous	assessment	of	MET	and	chromosome	7	signals	on	the	same	
tumor	sec4ons	vs.	break-apart	probe	for	the	lacer	with	a	separate	chromosome	2	
enumera4on	probe	on	adjacent	tumor	sec4ons;	and	b)	difficulty	some4mes	to	count	the	
exact	number	of	MET	signals	clustered	in	dense	clouds	whether	the	relevant	ra4o	had	to	be	
obtained.	
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Polysomy	of	chromosome	7	was	assessed	by	CEP7	probe	(centromeric	alpha-satellite	specific	
for	chromosome	7,	from	Abboc)	on	the	same	sec4ons	as	those	used	for	MET	gene	
evalua4on,	whereas	an	addi4onal	FISH	assay	was	performed	on	adjacent	sec4ons	for	
chromosome	2	u4lizing	CEP2	probe	(centromeric	alpha-satellite	specific	for	chromosome	2,	
from	Abboc).	Hence,	polysomy	was	designated	as	the	presence	of	more	than	two	specific	
signals	for	both	ALK	or	MET	and	chromosome	2	or	7	centromeric	probes,	respec4vely,	with	a	
ra4o	ranging	from	1.0	to	2.0	in	the	large	majority	of	tumor	cells.	ALK	or	MET	eusomy	and	
polysomy	were	aggregated	for	sta4s4cal	purposes	into	a	unique	category	of	nega4ve	tumors.	
Beyond	assembling	results	as	FISH	categories,	both	the	percentage	of	tumor	cells	harboring	
the	relevant	gene	altera4ons	(amplifica4on,	borderline	amplifica4on,	nega4ve	tumors)	and	
the	mean	value	of	signals	per	cell	were	introduced	into	the	analysis.		
Immunohistochemistry	
All	tumors	underwent	protein	characteriza4on	for	ALK	and	MET	gene	product	by	using	
sensi4ve	IHC	methods.	Briefly,	three-four	micron-thick	sec4ons	were	unmasked	with	EDTA	
buffer	at	pH8	for	30	minutes	and	made	react	with	the	relevant	an4bodies	(for	ALK,	clone	5A4,	
Santa	Cruz,	Heidelberg,	Germany,	dilu4on	1:100	for	60	min;	for	total	MET,	clone	D1C2,	Cell	
Signaling	Technology,	Denver,	MA,	USA,	dilu4on	1:100	for	60	min;	for	p-MET	at	Tyr1234/1235,	
clone	D26,	Cell	Signaling	Technologies,	dilu4on	1:50	for	30	min).	Sec4ons	were	then	
incubated	with	a	commercially	available	detec4on	kit	(EnVision™	FLEX+,	Dako,	Glostrup,	
Denmark)	in	an	automated	immunostainer	(Dako	Autostainer	System,	Dako,	Denmark)	
according	to	previously	refined	IHC	methods	14.	The	specificity	of	all	reac4ons	was	double-
checked	replacing	the	primary	an4body	with	a	non-related	mouse	immunoglobulin	at	a	
comparable	dilu4on	or	using	normal	serum	alone.	Posi4ve	and	nega4ve	controls	were	
adopted	as	required	(for	ALK,	a	FISH-posi4ve	pulmonary	adenocarcinoma	carrying	the	
specific	gene	rearrangement;	for	MET/p-MET,	the	alveolar	rhabdomyosarcoma	cell	line	RH30	
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characterized	by	strong	reac4vity	27).	Results	were	then	rendered	semi-quan4ta4vely	as	the	
percentage	of	labeled	cells	showing	convincing	cytoplasm	labeling	along	with	faint	to	strong	
membrane	decora4on	on	the	basis	of	the	specific	protein	being	inves4gated,	as	previously	
detailed	14.	
		
Real-4me	polymerase	chain	reac4on	
Total	RNA	from	microdissected	tumor	samples	with	at	least	75%	cellularity	was	isolated	by	
means	of	the	TRIzol	method	(Life	Technologies,	Foster	City,	CA,	USA)	and	reverse	transcribed	
to	cDNA	with	SuperScript®	Reverse	Transcriptase	(Life	Technologies,	USA)	using	both	oligo-dT	
and	random	hexamers.	ALK	and	MET	mRNA/cDNA	were	rela4vely	quan4fied	by	real-4me	PCR	
using	specific	TaqMan	assays	(Life	Technologies,	USA)	for	the	relevant	gene	isoforms	under	
evalua4on,	as	previously	detailed	28.	The	housekeeping	POL2	was	used	as	endogenous	
posi4ve	control	and	thus	amplified	simultaneously	with	the	samples.	The	levels	of	mRNA	for	
the	relevant	genes	were	quan4fied	in	tumor	samples	using	the	2	-	ΔCT	threshold	method	and	
then	compared	with	the	mRNA	thresholds	of	non-neoplas4c	paired	lung	samples,	always	
calibra4ng	each	case	with	the	housekeeping	gene	POL2	levels.	Acquisi4on	and	analysis	of	the	
data	was	performed	using	Sequence	Detec4on	System	ABIPRISM	7900HY	(Life	Technologies,	
USA).	All	experiments	were	performed	in	triplicate	for	consistency.			
Western	blot	
	 Cell	lysate	were	directly	separated	on	SDS-polyacrylamide	gels.	Standardized	
immunobloUng	protocols	were	used	to	assay	ALK	and	MET	protein	expression.	As	posi4ve	
control	for	expression	and	ac4va4on	of	MET	protein,	the	RH30	cell	line	was	adopted.	This	cell	
line	expresses	ALK	and	MET	protein	upon	IHC,	as	well	as	gene	copy	gain	by	FISH	(ALK	with	
5-12	signals	per	cell	and	MET	with	5-10	signals	per	cell).	Two	different	an4-ALK	an4bodies	
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recognizing	intracellular	kinase-containing	regions	of	ALK	were	used,	namely	mouse	
monoclonal	an4body	ALKc	provided	by	Dr	B.	Falini,	University	of	Perugia,	Italy,	and	the	
commercially	available	rabbit	monoclonal	an4body	to	ALK	clone	D5F3	(Cell	Signaling	
Technology®,	USA).	ALK	ac4va4on	was	tested	on	whole	lysate	(100μg)	using	the	phospho-
Tyr664ALK	an4body	(Cell	Signaling	Technology®,	USA).	MET	(D1C2)	XP®	rabbit	monoclonal	
an4body	and	a	polyclonal	rabbit	p-MET	(Tyr1234/1235)	an4body	(Cell	Signaling	Technology®,	
USA)	were	applied	to	whole	lysate	to	examine	MET	and	its	ac4va4on.	Nonetheless,	to	
observe	the	downstream	signaling	transduc4on	ac4va4on	pathways	of	ALK	and	MET,	the	
following	an4bodies	were	applied	to:	AKT,	p-AKT,	MAPK,	p-MAPK,	FAK,	p-FAK,	SRC,	p-SRC	(all	
from	Cell	Signaling	Technology,	®	USA).	Furthermore,	VINCULIN	(Cell	Signaling	Technology®,	
USA)	was	assayed	as	posi4ve	control	for	protein	loading.	
Sta4s4cal	analysis	 	
Qualita4ve	data	were	compared	by	Fisher’s	exact	probability	test	or	chi-square	test	as	
appropriate,	whereas	con4nuous	data	were	contrasted	with	Mann-Whitney	test.	The	
strength	of	associa4on	between	variables	showing	quan4ta4ve	categories	of	unequal	
magnitude	(i.e.	MET	and	ALK	gene	FISH	altera4ons)	was	evaluated	by	using	con4ngency	
coefficient	and	Cramer’s	V	(φc),	which	may	vary	between	0	(independence	or	no	associa4on)	
and	1	(dependence	or	complete	associa4on).	Overall	survival	(OS)	was	defined	as	the	4me	
between	surgery	and	the	last	follow-up	or	cancer	death.	If	a	pa4ent	died	without	cancer	
recurrence,	the	pa4ent's	survival	4me	was	censored	at	the	4me	of	death.	Only	lung	cancer-
related	deaths	or	recurrences	were	considered	to	be	events.	Disease-free	survival	(DFS)	was	
calculated	from	the	date	of	surgery	to	the	date	of	progression	or	the	date	of	last	follow-up.	
Survival	es4mates	were	calculated	with	Kaplan-Meier’s	method	and	compared	by	the	log	
rank	test.	The	Cox	propor4onal	hazard	regression	model	was	used	to	evaluate	the	
simultaneous	effect	of	explanatory	variables	on	survival	4me.	All	analyses	were	carried-out	
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using	the	SAS	sta4s4cal	soware	(SAS	Ins4tute,	Inc.,	Cary,	NC,	USA).	For	all	tests,	only	two-
sided	p-values	were	taken	into	account	(with	a	threshold	of	<0.05	for	sta4s4cal	significance)	
and	confidence	intervals	set	at	the	95%	level.	
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Results	
Pathology	
The	study	comprised	83	PLC,	5	PB,	4	GCC,	3	CS	and	3	SpCC.	Out	of	83	PLC,	73	tumors	showed	
an	epithelial	cell	component,	whereas	ten	were	composed	of	sarcoma-like	elements	only	
featuring	spindle	and	giant	cells.	Out	of	these	73	tumors,	53	included	adenocarcinoma	
ranging	from	to	10	to	90%,	15	squamous	cell	carcinoma	ranging	from	10	to	85%,	and	5	
adenosquamous	carcinoma	ranging	from	40	to	80%.	In	the	same	tumor	subtype,	the	
sarcoma-like	component	accounted	for	spindle	cells	in	24	and	giant	cells	in	nine	tumors	
(either	ranging	from	15	to	95%),	whereas	a	combina4on	of	spindle	and	giant	cells	were	
observed	in	50	tumors	to	range	from	10	to	100%.	
In	PB,	the	epithelial	component	comprised	well-differen4ated	fetal	adenocarcinoma	(ranging	
from	to	20	to	80%),	while	the	sarcomatous	component	featured	spindle	cells	of	adult	type	in	
2	tumors	and	blastematous	cells	with	rhabdomyosarcoma	elements	in	3	tumors	(ranging	
from	20	to	80%).	
In	CS,	the	epithelial	component	was	adenocarcinoma	in	two	cases	and	squamous	cell	
carcinoma	in	one	case,	averaging	30%	of	tumor	mass,	whereas	the	sarcoma	component	was	
rhabdomyosarcoma,	osteosarcoma	or	a	combina4on	of	either	tumor	type	(ranging	from	70	to	
90%).	
In	GCC	and	SpCC	there	was	an	exclusive	component	of	giant	or	spindle	cells,	respec4vely	
(Figure	1	A	and	1	D).	Lymph	node	metastases	were	of	epithelial	type	in	25	tumors	and	
sarcoma-like	in	16	tumors.	Apart	from	tumor	necrosis	amount,	no	other	rela4onship	was	
noted	between	tumor	stage	(dichotomized	as	stage	I	vs.	II-IV)	and	histological	classifica4on,	
tumor	cell	composi4on	and	vascular	invasion	(Supplemental	Material	A).	
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Distribu4on	of	MET	and	ALK	altera4ons	
Gene	amplifica4on,	borderline	amplifica4on,	eusomy	status	and	chromorome	2	or	7	
polysomy	were	iden4fied	in	25	(25.6%),	6	(6.1%),	16	(16.3%)	and	51	(52.0%)	tumors	and	16	
(16.3%),	9	(9.2%),	22	(22.5%)	and	51	(52.0%)	tumors	for	MET	and	ALK,	respec4vely.	No	ALK	
rearrangement	was	observed	in	the	tumor	series	under	evalua4on.	MET	amplifica4on	was	
mostly	characterized	by	variably	sized	clusters	up	to	clouds	of	signals	as	opposed	to	discrete	
single	signals	per	tumor	cell	for	ALK	(Figure	1	C	and	1	F).	A	close	rela4onship	was	no4ced	
between	MET	and	ALK	amplifica4on,	with	all	16	ALK-amplified	tumors	being	MET	co-
amplified	in	the	same	relevant	tumors	cells	that	in	turn	also	included	three	ALK-borderline	
amplified	and	six	ALK-nega4ve	tumors	(p<0.0001)	(Table	2).	The	strength	of	this	associa4on	
was	confirmed	by	con4ngency	coefficient	and	Cramer’s	V	(φc)	values	of	0.72.	All	the	cases	
showing	MET	or	ALK	FISH	amplifica4on	also	presented	with	higher	vales	of	the	relevant	ra4os	
between	gene	and	centromere	signals	(data	not	shown).	
As	far	as	the	percentage	of	altered	tumor	cells	was	concerned,	the	mean	value	was	
57.5±30.5%	(range	11%	to	69%)	for	MET-amplified	tumors	(22	PLC,	two	PB	and	one	CS)	and	
45.0±26.4%	(range	11%-43%)	for	ALK-amplified	tumors	(14	PLC	and	two	PB)	(p=0.0032),	while	
the	number	of	signals	per	cell	was	on	average	4.9±2.1%	for	MET	and	4.3±1.6%	for	ALK	
(p=0.0357).	No	differences	in	MET	and	ALK	altera4ons	were	found	between	epithelial	and	
sarcoma-like/sarcoma	elements.	For	MET	but	not	ALK,	the	relevant	amplifica4on	was	
marginally	associated	with	advanced	stage	(II-IV)	of	disease	(p=0.080)	and	an	increased	
percentage	of	altered	cells	(p=0.060).	A	significant	associa4on	was	documented	for	MET-
amplified	or	borderline-amplified	tumors	with	spindle	and	giant	cell	component	(p=0.046),	
whereas	no	associa4ons	were	seen	for	ALK	with	the	percentage	and	the	type	of	tumor	cells.	
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Protein	expression	
MET	(Figure	1	B)	and	p-MET	(Figure	2	A)	expression	was	present	as	membrane	decora4on	in	
most	tumor	cells	of	all	MET-amplified	and	MET-borderline	amplified	tumors,	whereas	fainter	
to	nega4ve	decora4on	was	observed	in	the	tumors	with	eusomy	for	the	relevant	gene	or	
chromosome	7	polysomy.	MET	or	p-MET	membrane	labeling	was	mainly	confined	to	
elements	featuring	epithelial	cells,	while	sarcoma-like/sarcoma	elements	were	either	
nega4ve	or	exhibited	vanishing	membrane	decora4on	only.	In	turn,	ALK	protein	was	always	
nega4ve	regardless	of	the	type	of	concurrent	gene	altera4on	(Figure	1	E).		
mRNA	expression		
Real-4me	PCR	examina4on,	carried	out	in	22	PLC	and	one	SpCC,	showed	detectable	levels	of	
MET	mRNA	in	six	MET-amplified,	one	MET-borderline	amplified	and	16	nega4ve	tumors,	
while	only	six	tumors	revealed	analyzable	thresholds	of	ALK	mRNA	compared	to	non-
neoplas4c	lung	parenchyma	(Supplemental	Material	B).	No	direct	rela4onship	was	observed	
for	either	gene	between	mRNA	levels	and	protein	expression,	FISH	altera4ons	or	clinico-
pathological	variables.	
Biochemical	assays	
	 Biochemical	inves4ga4on	was	feasible	on	8	PSC,	which	frozen	material	was	available	
for,	with	results	being	depicted	in	Figure	2	B.	As	posi4ve	control,	the	RH30	cell	line	showing	
gene	copy	gain	for	ALK	and	MET	was	adopted	(lane	1).	Out	of	the	8	tumor	samples	under	
evalua4on,	lane	2	refers	to	isolated	MET	amplifica4on,	lanes	3-5	to	MET	and	ALK	
simultaneous	co-amplifica4on,	lane	6	to	MET	and	ALK	borderline	co-amplifica4on	and	lanes	7	
through	9	to	nega4ve	tumors	(eusomy	or	chromosome	7	or	2	polysomy)	for	either	gene.	
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Interes4ngly,	while	ALK	total	protein	or	p-ALK	was	never	documented	in	our	cases,	
downstream	ac4va4on	was	seen	in	lines	2	to	6	with	bands	for	p-MET,	p-AKT	and	p-MAPK	in	
MET-posi4ve	cases,	which	comprised	isolated	MET	amplifica4on,	MET&ALK	co-amplifica4on	
and	MET&ALK	borderline	co-amplifica4on.	However,	there	were	worthwhile	differences	
among	these	tumors,	inasmuch	as	faint	to	strong	p-SRC	and	p-FAK	signals	were	present	only	
in	cases	exhibi4ng	simultaneous	MET&ALK	co-amplifica4on.	In	turn,	p-AKT	and	p-MAPK	were	
recognizable	even	in	not	amplified	tumors	for	either	MET	or	ALK,	which	failed	to	show	signals	
for	p-MET,	p-SRC	and	p-FAK	(lanes	7	to	9).	Interes4ngly,	there	was	a	prevalence	of	sarcoma-
like/sarcoma	cells	in	tumors	expressing	MET&ALK	co-amplifica4on	or	borderline	amplifica4on	
over	tumors	with	MET	amplifica4on	alone,	which	showed	a	prevalence	of	epithelial	cells	
(p=0.0001).	
Clinical	correla4ons	
	 Overall	survival	was	assessable	in	92	pa4ents	and	DFS	in	72	pa4ents.	No	associa4on	
was	seen	for	OS	and	DFS	with	ALK&MET	co-amplifica4on	as	opposed	to	borderline	
amplifica4on	and	nega4ve	tumors	(Supplemental	Material	C).	A	marginally	significant	shorter	
OS	but	not	DFS	was	documented	in	tumors	expressing	higher	percentage	of	MET-altered	cells	
(p=0.064),	whatever	type	of	altera4ons	were	dealing	with,	according	to	the	median	value	of	
61%.	Other	OS	determinants	were	pN	status	(p<0.0001),	the	percentage	of	metasta4c	LN	
(p=0.008)	and,	marginally,	vascular	invasion	(p=0.076)	and	the	percentage	of	tumor	necrosis	
(p=0.106).	Disease-free	survival	was	affected	by	pN	status	(p=0.028),	the	percentage	of	
metasta4c	LN	(p=0.006),	the	percentage	of	tumor	necrosis	(p=0.069)	and,	marginally,	MET	
average	signals	per	cell	according	to	the	median	value	of	4.4	(p=0.052).	No	survival	
rela4onship	was	seen	with	any	ALK	gene	altera4on.	Pa4ents	undergoing	neo-adjuvant	
chemotherapy	differed	marginally	from	untreated	pa4ents	for	DFS	(p=0.074)	but	not	OS	or	
other	bio-pathological	variables.	Mul4variate	survival	models	pushed	pN	status	(p=0.002)	
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and,	marginally,	higher	median	percentage	of	MET-altered	cells	(p=0.120)	to	emerge	for	OS	
and	pN	status	(p=0.010)	and,	marginally,	tumor	necrosis	(p=0.130)	and	higher	median	value	
of	MET	copy	gain	per	cell	(p=0.070)	to	emerge	for	DFS.	Notably,	tumor	stage	was	did	not	
independently	affect	survival	(see	Table	3	for	details). 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Discussion	
The	main	findings	of	our	inves4ga4on	are	that	MET	amplifica4on	is	present	in	a	subset	of	PSC	
and	is	a	poten4al	valuable	target	for	therapy	op4ons	in	a	currently	orphan	tumor	with	
ineffec4ve	treatments	other	than	surgical	excision	Accordingly,	MET	amplifica4on	may	be	
really	an	Achilles	heel	in	this	clinical	seUng	of	tumors,	inasmuch	as	it	may	be	effec4vely	
targeted	by	specific	tyrosine	kinase	inhibitors.	
	 Our	inves4ga4on	displayed	a	very	close	correla4on	between	MET	and	ALK	altera4ons	
upon	FISH	analysis,	with	about	one	fih	of	PSC	showing	co-amplifica4on	for	both	genes,	as	
also	confirmed	by	high	thresholds	of	con4ngency	coefficient	and	Cramer’s	V	sta4s4cs.	In	turn,	
no	ALK	rearrangement	was	observed	in	PSC	as	previously	reported	14.	An	immediate	
conten4on	is	that	these	cytogene4c	aberra4ons	are	non-random	events	in	PSC,	where	are	
likely	to	play	addic4on	mechanisms	to	the	development	and	maintenance	of	at	least	a	subset	
of	them.	While	ALK	rearrangement	was	never	observed	and	MET	muta4on	not	evaluated	in	
the	present	study	as	recently	pointed	out	11,	12,	we	noted	that	MET-amplified	tumors	
prevailed	over	ALK-amplified	tumors	as	either	the	number	of	altered	cases	or	the	amount	of	
involved	tumor	cells,	in	both	epithelial	and	sarcoma-like/sarcoma	components.	These	data	
sustained	not	only	a	driver	role	of	MET	amplifica4on	in	the	genesis	of	a	few	PSC,	but	also	
suggested	a	non-negligible	and	causa4ve	effect	of	concurrent	ALK	as	co-actor	despite	
undetectable	protein	accumula4on	even	in	amplified	and	borderline-amplified	tumors.	
However,	experiments	conducted	by	exploi4ng	very	sensi4ve	immunofluorescence	
techniques	revealed	that	there	was	faint	accumula4on	of	ALK	protein	in	the	cytoplasm	of	
ALK-amplified	but	not	borderline-amplified	tumors,	which	failed	however	to	be	
demonstrated	with	bright-field	IHC	or	western	blot	analysis	probably	due	to	the	higher	
sensi4vity	of	the	immunofluorescence	approach	(data	not	shown).	As	a	macer	of	fact	very	
low	levels	of	ALK	mRNA	were	otherwise	detected	by	means	of	real-4me	PCR	as	opposed	to	
complete	absence	in	normal	lung	parenchyma	of	the	same	pa4ents.	
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Furthermore,	we	confirmed	our	previous	observa4ons	14	that	ALK	or	MET	amplifica4on	was	
closely	associated	with	chromosome	7	or	chromosome	17	polysomy	but	neither	EGFR	nor	
Her-2/neu	amplifica4on,	thus	minimizing	the	risk	of	facing	with	pan-amplifica4on	linked	to	
clonal	selec4on,	tumor	progression	or	chromosome	instability	of	highly	malignant	lesions	
(data	not	shown).	The	func4onal	role	of	MET	as	driver	mechanism	in	a	few	PSC	was	also	
endorsed	by	the	prevalence	of	total	MET-	and	p-MET-protein	accumula4on	in	amplified	and	
borderline	amplified	tumors,	while	nega4ve	lesions	(bearing	eusomy	or	polysomy	status)	
turned	out	faintly	decorated	for	total	MET	but	consistently	nega4ve	for	p-MET,	sugges4ng	the	
presence	of	only	func4onally	inac4ve	receptor	in	these	tumors.	
	 The	magnitude	of	MET	amplifica4on	intended	as	the	higher	percentage	of	amplified	
cells	in	amplified	and	borderline-amplified	cases	compared	to	the	relevant	ALK	recruitment	
indicated	that	MET	amplifica4on	was	the	driver	event	in	this	subset	of	PSC,	while	ALK	
amplifica4on	occurred	as	a	second	hit	to	strengthen	the	biological	mechanism	of	this	gene	
altera4on.	This	hypothesis	was	further	reinforced	by	the	observa4on	that,	out	of	nine	PSC	
iden4fied	as	bearing	ALK-borderline	amplifica4on,	there	were	three	MET	amplified	and	five	
MET	borderline-amplified	tumors,	with	only	one	case	bearing	eusomy	for	the	relevant	gene	
altera4on.	On	the	contrary,	out	of	six	MET-borderline	amplified	tumors,	there	were	one	ALK-
nega4ve	and	five	ALK	borderline	amplified	tumors.	
No	direct	rela4onship	was	documented	between	mRNA	content	and	protein	expression	or	
any	FISH	altera4on	for	both	MET	and	ALK,	sugges4ng	some	post-transcrip4onal	and	non-
linear	regula4on	mechanisms.	While	MET	membrane	expression,	along	with	darker	
cytoplasm	decora4on	was	present	in	the	majority	of	cases	regardless	of	their	cytogene4c	
altera4on,	p-MET	IHC	paralleled	func4onal	biochemistry	results	indica4ng	that	only	those	
cases	with	MET	gene	amplifica4on	were	also	posi4ve	for	p-MET	by	IHC,	whereas	cases	
without	the	protein	ac4va4on	turned	out	to	be	completely	nega4ve.	Interes4ngly,	in	the	
specific	cases	with	MET	amplifica4on,	p-MET	IHC	was	stronger	in	epithelial	cells	while	
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decreased	in	intensity	and	vanished	as	soon	as	sarcoma-like/sarcoma	cell	status	were	
reached.	This	finding	was	in	keeping	with	the	assump4on	that	MET	is	one	of	the	actors	
playing	a	role	in	EMT	occurring	in	lung	cancer,	which	stably	characterizes	PSC	2.	In	this	
respect,	only	MET&ALK	co-amplifica4on	turned	out	in	mul4-signal	ac4va4on	cascade	
including	p-SRC	and	p-FAK	beyond	p-MET,	p-AKT	and	p-MAPK,	which	are	common	to	both	
ALK	and	MET	downstream	pathways	leading	to	increased	cell	mo4lity,	invasion	ability	and	
EMT	occurrence	29,	30.	Conversely,	isolated	MET	amplifica4on	or	MET&ALK	borderline	co-
amplifica4on	(all	our	ALK-amplified	tumors	were	also	MET-amplified)	resulted	in	MET	
ac4va4on	(with	p-MET	upon	IHC	and	biochemical	assays)	along	with	p-AKT	and	p-MAPK	only.	
Furthermore,	there	was	a	significant	rela4onship	between	MET&ALK	co-amplifica4on	and	the	
prevalence	of	sarcoma-like/sarcoma	elements	in	the	relevant	tumors	(p=0.0001),	suppor4ng	
once	again	a	causa4ve	role	of	both	genes	in	sustaining	mechanisms	of	EMT	in	a	subset	of	PSC.	
Our	findings	support	the	view	that	other	factors	were	likely	to	play	an	ac4ve	role	in	inducing	
EMT	in	PSC	when	lacking	complete	MET&ALK	co-amplifica4on.	Tumors	harboring	eusomy	for	
MET	or	ALK	or	polysomy	for	the	relevant	chromosome	exhibited	p-AKT	and	p-MAPK	but	not	
p-MET	(p-ALK	was	never	seen	in	func4onal	tests),	indica4ng	that	different	mechanisms	of	
EMT	occurred	in	PSC.	The	close	co-linearity	between	MET	and	ALK	aberra4ons	pushed	the	
gene	copy	gain	to	emerge	as	causa4ve	inducer	of	the	type	of	signal	cascade	being	ac4vated.	
In	this	regard,	a	MET&ALK	copy	number	gain	consistent	with	amplifica4on	caused	SRC	and	
FAK	pathway	to	recruit,	whilst	lower	gene	copy	gain	failed	to	ac4vate	the	same	pathway	
effec4vely.	Interplaying	between	different	oncogenes	due	to	co-ac4va4on	is	not	surprising	in	
lung	cancer	and	may	define	dis4nct	subsets	of	tumors	with	different	biological	proper4es	and	
clinical	outcome	31.				
Clinical	correla4ons	showed	that	MET	but	not	ALK	FISH	altera4ons	were	weak	prognos4c	
factors,	whereas	the	value	of	our	observa4ons	regarded	the	opportunity	to	use	MET	and	ALK	
as	poten4al	co-targets	of	therapy.	Recent	data	stemming	from	preclinical	analyses	and	early-
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phase	clinical	trials	in	NSCLC	other	than	PSC	have	demonstrated	that	ALK	and	MET	inhibitors	
specifically	reduced	prolifera4on	in	tumors	carrying	either	rearrangement	or	amplifica4on,	
and	that	MET	protein	accumula4on	and	gene	amplifica4on	were	predictors	of	response	in	
NSCLC	to	the	treatment	with	MET	monoclonal	an4bodies	or	tyrosine	kinase	inhibitors	32.	
There	are	no	systema4cal	data	on	the	predic4ve	role	of	ALK	amplifica4on	in	lung	cancer,	but	
NSCLC	cells	driven	by	ALK	amplifica4on	and	oncogenic	rearrangements	of	ROS1	and	RET	
kinase	genes	have	been	shown	to	be	sensi4ve	to	ganetespib	exposure,	a	Hsp90	inhibitor	33.	
This	reinforces	once	again	the	no4on	that	ALK	amplifica4on	could	be	the	4p	of	the	iceberg	of	
other	underlying	gene	altera4ons,	which	in	our	study	involved	MET	gene	in	a	subset	of	
tumors.		
Muta4onal	events	of	MET	have	recently	been	reported	to	occur	in	PSC	11,	12,	but	results	are	
conflic4ng	about	the	rela4ve	prevalence	of	muta4ons	ranging	from	less	than	5%	12	to	22%	
11,	hence	revealing	an	unexpected	inter-tumor	heterogeneity	likely	due	to	geography,	
ethnicity	and	gender	issues	or	tumor	composi4on.	Few	papers	have	thus	far	inves4gated	the	
causa4ve	rela4onship	between	MET	or	ALK	gene	muta4ons	and	copy	number	varia4ons,	but	
this	associa4on	seems	unlikely	to	occur	in	diverse	sets	of	tumors34,	35.	As	these	events	could	
even	point	to	different	cohorts	of	pa4ents,	it	is	important	for	biological	and	clinical	reasons	to	
compare	the	muta4onal	burden	of	PSC	by	using	high-throughput	methods,	such	as	next	
genera4on	sequencing,	with	the	underlying	copy	number	varia4on	by	means	of	reproducible	
techniques,	such	as	FISH	analysis	(Pelosi	et	al,	manuscript	in	prepara4on).	As	a	macer	of	fact	
establishing	the	rela4onship	between	gene	amplifica4on	and	muta4onal	status	may	provide	
meaningful	informa4on	on	secondary	resistance	mechanisms	while	using	tyrosine	kinase	
inhibitors.	
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Conclusions	
We	herein	have	documented	a	likely	causa4ve	co-ac4va4on	of	MET	and	ALK	in	the	
development	and	maintenance	of	a	subset	of	PSC	and	validated	FISH	as	the	best	
methodology	to	test	this	par4cular	subgroup	of	tumors.	These	findings	pave	the	way	to	the	
clinical	use	of	targeted	therapy	based	on	specific	pathway	inhibitors.	
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Figure	legends	
Figure	1	A-F.	Pulmonary	sarcomatoid	carcinoma	of	giant	cell	type	is	shown	(A),	which	was	
posi4ve	for	MET	protein	(B)	and	exhibited	MET	gene	amplifica4on	as	indicated	by	the	
presence	of	over	15	copies	of	fluorescence	signal	per	cell	in	more	than	10%	of	tumor	cells	(C).	
Another	example	of	pulmonary	sarcomatoid	carcinoma	of	pleomorphic	cell	type	comprising	
spindle	and	giant	cells	is	depicted	(D),	showing	complete	absence	of	ALK	protein	(E)	and	a	
dis4nct	signal	pacern	indica4ng	ALK	gene	amplifica4on	(F).	
Figure	2	A-B.	Pulmonary	sarcomatoid	carcinoma	of	pleomorphic	type	with	posi4ve	p-MET	
immunohistochemistry	in	the	epithelial	cell	component	is	shown,	whereas	adjacent	sarcoma-
like	elements	are	nega4ve	(A).	The	panel	of	western	blot	analysis	is	presented	according	to	
diverse	lanes	corresponding	to	different	tumor	categories.	At	variance	with	MET-amplified	
tumors	(lane	2),	MET&ALK	borderline	amplified	tumors	(lane	6)	and	nega4ve	tumors	with	
eusomy	or	chromosome	polysomy	(lanes	7	to	9),	tumors	exhibi4ng	concurrent	MET	and	ALK	
amplifica4on	presented	with	different	pathways	of	ac4va4on	involving	p-SRC	and	p-FAK.	This	
indicated	that	it	was	the	en4ty	of	gene	copy	gain	for	MET	and	ALK	to	affect	the	ul4mate	
func4onal	modality	of	ac4vated	downstream	signals.	RH30	rhabdomyosarcoma	cell	line	is	
shown	in	lane	1,	which	exhibited	posi4ve	ALK	and	MET	immunohistochemistry	and	gene	copy	
gain	for	ALK	(5-12	signals)	and	MET	(5-10	signals)	(B).	
Supplemental	Material	A.	Pathological	results	organized	according	to	tumor	stage.	Only	
necrosis	amount	was	significantly	associated	with	more	advanced	tumor	stage	(p=0.003).				
Supplemental	Material	B.	Real-4me	PCR	analysis	results	for	MET	and	ALK		according	to	FISH	
results	and	some	clinico-pathologic	variables.	No	direct	rela4onship	was	observed	for	either	
gene	between	mRNA	levels	and	protein	expression,	FISH	altera4ons	or	clinico-pathological	
variables.		
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Supplemental	Material	C.	Overall	or	disease-free	survival	was	not	affected	by	MET	and	ALK	
FISH	co-amplifica4on	as	contrasted	to	borderline	amplifica4on	and	nega4ve	tumors.  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